Editorial: Post-Exposure Prophylactic Neutralizing Monoclonal Antibodies to SARS-CoV-2 for Individuals at High Risk for COVID-19사설: COVID-19 고위험군 개인을 위한 SARS-CoV-2에 대한 노출 후 예방 중화 단일클론 항체Editorial Published on 2021-08-162022-09-11 Journal: Medical science monitor : international medical jo [Category] SARS, 변종, 진단, [키워드] accelerated acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 approval approvals approved authorization bamlanivimab Casirivimab children clinical development Clinical studies clinical study coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 progression diagnostic drug editorial Effectiveness Emergency Emergency use Emergency use authorization etesevimab EUA exposure to FDA food high risk Imdevimab individual initial Mild mild to moderate Moderate COVID-19 monoclonal antibody monotherapy Neutralizing neutralizing monoclonal antibodies neutralizing monoclonal antibody Older pandemic Preclinical Prevent progression Prophylactic REGEN-COV Regulatory Regulatory Authorities respiratory SARS-CoV-2 severe acute respiratory syndrome Coronavirus severe COVID-19 therapeutic therapy treat US Food and Drug Administration Vaccine variants of SARS-CoV-2 [DOI] 10.12659/MSM.934393 PMC 바로가기 [Article Type] Editorial
Central blood pressure lowering effect of telmisartan‐rosuvastatin single‐pill combination in hypertensive patients combined with dyslipidemia: A pilot studyRandomized Controlled Trial Published on 2021-08-122022-10-04 Journal: Journal of clinical hypertension (Greenwich, Conn. [Category] MERS, SARS, 임상, [키워드] angiotensin II receptor blocker baseline benefit blood pressure brachial cardiovascular central blood pressure change changed Combination Compliance COVID‐19 defined dyslipidemia effective Efficacy evaluate group had no hypertension hypertensive patient inclusion criteria monotherapy multicenter no significant difference pandemic Patient pilot study Prospective pulse Randomized reduced risk Rosuvastatin SBP significant difference significantly telmisartan therapy were assessed [DOI] 10.1111/jch.14345 PMC 바로가기 [Article Type] Randomized Controlled Trial
Shutting the gate before the horse has bolted: is it time for a conversation about SARS-CoV-2 and antiviral drug resistance?말이 달려들기 전에 문을 닫으십시오: SARS-CoV-2와 항바이러스제 내성에 대한 대화가 필요한 시점입니까?Review Published on 2021-08-122022-09-11 Journal: Journal of Antimicrobial Chemotherapy [Category] SARS, 치료제, [키워드] Antiviral antiviral drug antiviral therapy class COVID-19 COVID-19 treatment Critical deliberation drug drug resistance drug target Efficacy HIV Influenza Influenza virus mechanism monotherapy Mutation provide Research resistance SARS-CoV-2 SARS-CoV-2 viral stimulate Treatment Variability virus widespread [DOI] 10.1093/jac/dkab189 PMC 바로가기 [Article Type] Review
Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities Reviews Published on 2021-08-092022-10-05 Journal: British Journal of Cancer [Category] 변종, 신약개발, [키워드] acquisition adaptive mechanism Cancer Cell Chemotherapy clinical benefit clinical trials clinically Complete contribute EGFR epidermal growth factor Evidence Evolution highlight information inhibitor lung adenocarcinoma lung cancer lung cancer patient mechanism monotherapy Mutation mutations pathway Patient potential mechanism progression provide Radiographic receptor Regulatory responses selective survival therapeutic Therapies therapy TKIs tyrosine [DOI] 10.1038/s41416-021-01519-2 [Article Type] Reviews
Combination Treatment With Remdesivir and Ivermectin Exerts Highly Synergistic and Potent Antiviral Activity Against Murine Coronavirus Infection렘데시비르와 이버멕틴의 병용 치료는 쥐 코로나바이러스 감염에 대해 높은 시너지 효과와 강력한 항바이러스 활성을 나타냅니다.Cellular and Infection Microbiology Published on 2021-07-302022-09-11 Journal: Frontiers in Cellular and Infection Microbiology [Category] MERS, SARS, 치료제, [키워드] activity Against antiviral drug antiviral therapy Betacoronavirus Betacoronavirus genus both viruses Cell Chloroquine clinical clinical trial clinical trials Combination combination therapy combination treatment coronavirus COVID-19 COVID-19 pandemic cytokine level develop doxycycline drug drug therapy effective Efficacy evaluated exhibited Hepatitis highest IC50 IL-6 in vitro model in vivo experiment indicated infect Infection inhibitory investigated Ivermectin ivermectin treatment leukemia Live virus lowest Macrophage macrophages mechanism MHV mice monotherapy murine hepatitis virus potent RAW264.7 macrophage cells reduction Remdesivir Replication Safe SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 infections selectivity index sequence identity significant reductions synergism synergistic tested the Betacoronavirus the disease therapy TNF-α Treatment Trial urgency viability Viral Viral RNA virus viruses [DOI] 10.3389/fcimb.2021.700502 PMC 바로가기 [Article Type] Cellular and Infection Microbiology
Arbidol is associated with increased in-hospital mortality among 109 patients with severe COVID-19: A multicenter, retrospective studyResearch Theme 1: COVID-19 Pandemic Published on 2021-07-172022-10-31 Journal: Journal of Global Health [Category] COVID-19, [키워드] 95% confidence interval addition adjusted age Analysis analyzed antiviral agent antiviral therapy antiviral treatments Arbidol association co-morbidities Combination complications COVID-19 patients demographics determine died discharged Effect Effectiveness enrolled hospital Hospitalization IFN-α in-hospital mortality indicated interferon-alpha Intervention Laboratory Logistic regression monotherapy multicenter Odds ratio oseltamivir other treatment Patient Prognosis Result Retrospective study ribavirin severe COVID-19 patient severe COVID-19 patients survival Treatment variables Wuhan, China [DOI] 10.7189/jogh.11.05017 PMC 바로가기 [Article Type] Research Theme 1: COVID-19 Pandemic
Integrative resource for network-based investigation of COVID-19 combinatorial drug repositioning and mechanism of actionResearch article Published on 2021-07-142022-10-05 Journal: Patterns [Category] 신약개발, 치료제, [키워드] approach clinicians and researchers combination therapy complementary complex COVID-19 drug drug combination drug target DSML 3: Development/Pre-production: Data science output has been rolled out/validated across multiple domains/problems effective in silico information mechanism of action monotherapy multifactorial pathology Pathways platform protein-protein interaction provide Quantitative resource SARS-COV-2 infection similarity treating COVID-19 [DOI] 10.1016/j.patter.2021.100325 [Article Type] Research article
The Use of Single Therapy With Tocilizumab Versus Combination Therapy With Remdesivir and Tocilizumab in SARS-CoV-2 Patients in El Paso, TexasInternal Medicine Published on 2021-07-132022-10-31 Journal: Cureus [Category] COVID-19, [키워드] 24 hour 24 hours Admission benefit Clinical guidelines clinical outcomes Combination combination therapy comparative observational study COVID-19 determine eligible evaluated Evidence globe group Infection laboratory biomarker management median Methylprednisolone monotherapy Mortality observation outcome P-value patients patients with SARS-CoV-2 Randomized controlled trial RDV Regression Remdesivir reported risk SARS CoV-2 SARS-CoV-2 SARS-CoV-2-infected patient screened Standard of care statistically significant statistically significant difference steroid TCZ therapeutic options therapy Tocilizumab Ventilation were given [DOI] 10.7759/cureus.16351 PMC 바로가기 [Article Type] Internal Medicine
The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort studyArticles Published on 2021-07-082022-10-29 Journal: The Lancet Rheumatology [Category] COVID-19, [키워드] 95% CI All participant B.1.1.7 variant BNT162b2 BNT162b2 vaccine Cellular immune response cellular response clinical effectiveness Cohort cohort study consecutive patient Control controls Coverage COVID-19 vaccine COVID-19 vaccine trials defined determine Diagnosis Dilution East eligible England evaluate evaluated extended interval females finding first dose foundation funding groups healthy control healthy controls humoral Humoral immunity IL-17 IL-2 IL-21 IL-23 immune response Immune-mediated inflammatory disease immunogenicity Immunosuppressant Immunosuppression individual inhibitors inhibitory interferon-γ IQR London lowest males median median age methotrexate monotherapy Necrosis neutralising antibody response Neutralising titre NHS of BNT162b2 participant Participants Patient Pfizer-BioNTech preserved Primary outcome receive receiving recruited Seven significantly lower single dose South spike glycoprotein spike-specific T-cell response study population the healthy the SARS-CoV-2 therapeutic Therapies Thoma TNF Trust vaccination vaccine immunogenicity Volunteer were excluded white wild-type SARS-CoV-2 [DOI] 10.1016/S2665-9913(21)00212-5 PMC 바로가기 [Article Type] Articles
Pathogenic implications, incidence, and outcomes of COVID-19 in autoimmune inflammatory joint diseases and autoinflammatory disordersReview Published on 2021-07-082022-10-28 Journal: Advances in Rheumatology (London, England) [Category] COVID-19, [키워드] acute respiratory syndrome anti-TNF therapies Autoimmune autoinflammatory disease caused cohorts coronavirus coronavirus disease COVID-19 COVID-19 incidence CVD Cytokine storm syndrome develop diabetes disease Diseases disorder disorders displaying Hospitalization hypertension immunosuppressive Implications incidence increased risk Infection Inflammatory Innate immunity joint Lung disease Male sex monotherapy Older age Other outcome pandemic pathogenic mechanism Patient presence of comorbidity psoriatic arthritis question raised renal rheumatoid arthritis risk factor SARS-CoV-2 SARS-COV-2 infection severe COVID-19 severity shown specific patient group Spondiloarthritis Spread susceptibility Taking therapy virus [DOI] 10.1186/s42358-021-00204-5 PMC 바로가기 [Article Type] Review